Skip to main content

Year: 2024

Kitron signs contract for marine IoT technology

(2024-12-23) Kitron has entered into a manufacturing contract with a leading technology company focusing on innovative IoT solutions. A five-year contract has been signed, and Kitron has received orders totalling EUR 15 million for delivery in 2025. The contract covers a gateway to sensors that transfer data to the cloud. The target application is assets tracking, monitoring shipments in the logistics sector. “We are extremely happy that the customer has chosen Kitron as a long-term production partner for its innovative IoT offering. Connectivity, including IoT, is one of Kitron’s prioritized market sectors, so this fits perfectly with our strategy,” said Mindaugas Sestokas, VP Central Eastern Europe. Production will take place at Kitron’s facility in Kaunas, Lithuania, and the scope is high-level assembly. For further...

Continue reading

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufacturing capacity. The majority of these improvements have already been addressed, and Fagron is collaborating with the FDA to clarify any outstanding items and achieve a satisfactory resolution. After the June inspection, the Company responded to the FDA on July 19, August 30, September 27, October 25, and November 22, 2024 addressing the Agency’s...

Continue reading

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesPneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlersParis, December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease. Despite decades of public health vaccination programs, invasive pneumococcal disease (IPD) continues...

Continue reading

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nomination USD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studiesAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The new funding supports the progression of Basilea’s novel antibiotic candidate BAL2420 (LptA inhibitor) towards the start of first-in-human...

Continue reading

Information release calendar for 2025

Interim information of Grigeo Group AB will be prepared and financial results will be released on these dates:February 25, 2025 – Interim Financial Statements for 12 months of 2024. April 8, 2025 – Annual audited Financial Statements for the year 2024. May 23, 2025 – Interim Financial Statements for 3 months of 2025. August 22, 2025 – Interim Financial Statements for 6 months of 2025. November 21, 2025 – Interim Financial Statements for 9 months of 2025.On April 30, 2025, the Company plans to hold an ordinary general meeting of shareholders. Tomas Jozonis Chief Executive Officer +370 5 243 58 01

Continue reading

Sun Country Airlines Debuts First Ever Custom Aircraft Livery Celebrating Minnesota Golden Gopher Athletics

Sun Country Gopher Athletics LiverySun Country Airlines Gopher Athletics LiveryMINNEAPOLIS, Dec. 21, 2024 (GLOBE NEWSWIRE) — Sun Country Airlines (NASDAQ: SNCY) debuted its first custom-designed aircraft livery in celebration of Minnesota Golden Gopher Athletics. Sun Country was named the Official Airline of Gopher Athletics in 2023. In addition, Sun Country has provided charter service for the university’s sports teams since 2012 and has flown nearly 500 charters during the past 12 years. “Sun Country is proud to debut this aircraft design that illustrates our hometown pride and longstanding partnership between two iconic Minnesota organizations,” said Grant Whitney, Senior Vice President and Chief Revenue Officer. “We look forward to continuing our multi-year partnership with Gopher Athletics and will root...

Continue reading

EHang Partners with Changan Automobile on Flying Cars to Create an Innovative Way for Personal Transportation

GUANGZHOU, China, Dec. 21, 2024 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading Urban Air Mobility (“UAM”) technology platform company, today announced the signing of a strategic cooperation agreement with Chongqing Changan Automobile Co., Ltd., (“Changan Automobile”), a leading Chinese car manufacturer listed on the Shenzhen Stock Exchange (ticker symbol:000625), in the presence of the Chongqing Municipal Government and representatives from various industry sectors. The parties will collaborate on the research and development, manufacturing, sales, and operation of flying car-related products, including electric vertical takeoff and landing (“eVTOL”) aircraft and innovative flying cars. Leveraging EHang’s strong product development capabilities...

Continue reading

Edf: Update on the Flamanville EPR: the reactor produces its first electrons on the national electricity grid

Update on the Flamanville EPR: the reactor produces its first electrons on the national electricity grid 21 December 2024 – EDF teams have achieved the first connection of the Flamanville EPR to the national grid at 11:48am. The reactor is now generating electricity. Since the first nuclear reaction on 3 September 20241, EDF teams have conducted a series of tests and inspections to gradually increase the reactor’s power. Flamanville 3 reactor was connected to the national grid on 21 December 2024 at 11:48am and has produced 100 MW of electricity. Luc Rémont, Chairman and CEO of EDF stated: “The coupling of the Flamanville EPR is a historical moment for the entire nuclear sector. I would like to salute all the teams who have met the challenges encountered during this project with the greatest tenacity and never compromising...

Continue reading

BNP PARIBAS GROUP: Signing of the share purchase agreement for AXA Investment Managers by BNP Paribas Cardif

  SIGNING OF THE SHARE PURCHASE AGREEMENT FOR AXA INVESTMENT MANAGERS BY BNP PARIBAS CARDIF Press releaseParis – 21 December 2024 After entering into exclusive negotiations on August 1st, AXA and BNP Paribas Cardif announce the signing of the Share Purchase Agreement for AXA Investment Managers (AXA IM). This signing follows the completion of the information-consultation procedure on strategic issues with the relevant employee representative bodies of both AXA and BNP Paribas groups. “This signing marks an important step in the acquisition process of AXA IM and our long-term partnership with AXA. In anticipation of the closing process, all teams are now working to welcome AXA IM’s employees and customers into the BNP Paribas Cardif Group” said Renaud Dumora, Chairman of BNP Paribas Cardif, Deputy COO of BNP Paribas. As previously...

Continue reading

Giftify, Inc. Announces Registered Direct Offering – CORRECTED

SCHAUMBURG, IL, Dec. 20, 2024 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, today announced that it intends to offer its securities in a registered direct offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Craft Capital Management, LLC is acting as the exclusive placement agent for the offering. The proposed offering of the securities described above is being offered by the Company pursuant to a “shelf” registration...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.